Actively Recruiting
Phase 12 Study of STX-478 Tersolisib Alone and With Other Cancer Drugs for Advanced Solid Tumors with PI3K Mutations
Led by Eli Lilly and Company · Updated on 2026-07-07
880
Participants Needed
65
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating STX-478 LY4064809, a mutant-selective PI3K inhibitor, in participants with advanced solid tumors that have PI3K mutations. This multipart, open-label phase 12 study aims to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of STX-478. The study includes participants with various solid tumors, including hormone receptor positive breast cancer, gynecologic cancers, head and neck squamous cell carcinoma, endometrial cancer, and others expressing the relevant mutation. The study has three parts Part 1 evaluates STX-478 alone in advanced solid tumors Part 2 assesses STX-478 combined with fulvestrant in hormone receptor positive breast cancer Part 3 studies STX-478 combined with endocrine therapy and a CDK46 inhibitor such as Ribociclib, Palbociclib, or Abemaciclib in the same breast cancer group. Each part starts with a 28-day screening period followed by treatment with STX-478 as monotherapy or in combination with other antineoplastic agents, tailored to specific cohorts. Participants undergo assessments including safety monitoring for dose-limiting toxicities within the first 28 days, pharmacokinetic measurements, and evaluation of tumor response over 12 months. Researchers also track treatment-emergent adverse events and changes in biomarkers such as circulating tumor DNA and glucose metabolism markers. Participants are monitored regularly during treatment and follow-up to evaluate the effects and safety of the study therapies.
CONDITIONS
Brief Title
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here